Patient Reported Outcomes/Quality of Life

PV QA 4 - Poster Viewing Q&A 4

TU_42_3728 - Meta-analysis of genome-wide association studies (GWAS) of late toxicity in 3,874 men treated with radiation for prostate cancer

Tuesday, October 23
2:45 PM - 4:15 PM
Location: Innovation Hub, Exhibit Hall 3

Meta-analysis of genome-wide association studies (GWAS) of late toxicity in 3,874 men treated with radiation for prostate cancer
S. L. Kerns1, L. Fachal2, L. Dorling2, G. Barnett3, N. Burnet3, M. Sydes4, D. Dearnaley5, A. Dunning2, P. Pharoah2, M. B. Parliament6, N. H. Usmani7, K. de Ruyck8, H. Ostrer9, B. S. Rosenstein10, A. Gomez CaamaNo11, A. Carballo12, P. M. Peleteiro Higuero12, A. Vega13, C. M. L. West14, and E. Hall15; 1University of Rochester Medical Center, Rochester, NY, 2University of Cambridge, Cambridge, United Kingdom, 3Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom, 4Medical Research Council, London, United Kingdom, 5The Institute of Cancer Research/The Royal Marsden NHS Foundation Trust, London, United Kingdom, 6Cross Cancer Institute - Alberta Health Services, Edmonton, AB, Canada, 7University of Alberta, Edmonton, AB, Canada, 8Ghent University, Ghent, Belgium, 9Albert Einstein College of Yeshiva University, New York, NY, 10Icahn School of Medicine at Mount Sinai, New York, NY, 11H Clínico Universitario, Santiago de Compostela, Spain, 12Complexo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain, 13Universidade de Santiago de Compostela, Santiago de Compostela, Spain, 14Division of Cancer Sciences, Manchester Academic Health Science Centre, University of Manchester, The Christie NHS Foundation Trust, Manchester, United Kingdom, 15The Institute of Cancer Research, London, United Kingdom

Purpose/Objective(s): Late toxicity following prostate cancer radiotherapy negatively impacts quality of life and can be dose-limiting. Radiosensitivity is a genetic trait, and identification of single nucleotide polymorphisms (SNPs) associated with toxicity could uncover novel radiobiology pathways and contribute to precision cancer care. The largest study to date meta-analyzed data from 1,564 men with prostate cancer and identified two risk SNPs. This expanded study added new cohorts to greatly increase the sample to 3,874 men with the aim of identifying new toxicity risk SNPs and validating previously identified SNPs.

Materials/Methods: A GWAS meta-analysis was performed with six independent cohorts of men treated with radiotherapy for prostate cancer: RAPPER (n=2,010), RADIOGEN (n=658), GenePARE (n=495), UGhent (n=311), CCI-BT (n=252), and CCI-EBRT (n=148). Four toxicities were assessed prospectively from 6 months after radiotherapy and harmonized to a common scale: increased urinary frequency, decreased urine stream, hematuria, and rectal bleeding. Germline DNA was genotyped using genome-wide arrays. Imputation generated a uniform set of ~7 million SNPs (frequency in Europeans >4%) across cohorts. Cox proportional hazards regression tested association between each SNP and time to first occurrence of grade 2 or worse toxicity within each cohort. Individual cohort results were combined using inverse variance weighted fixed-effects meta-analysis. Novel SNP-toxicity associations were considered significant if they had meta-p-value <5x10-8. Bayesian False Discovery Probability (BFDP) provided an additional measure of confidence.

Results: Five new risk loci for late toxicity were identified in 3,874 prostate cancer patients: rs17055178 (HR 1.98; 95%CI 1.60 to 2.44; p=2.4x10-10; BFDP <1%) and rs9644474 (HR 0.47; 95%CI 0.36 to 0.62; p=4.3x10-8; BFDP 10%) associated with rectal bleeding; rs10969913 (HR 3.82; 95%CI 2.50 to 5.83; p=6.2x10-10; BFDP 1.6%) with decreased urine stream; rs11122573 (HR 1.89; 95%CI 1.50 to 2.38; p=2.3x10-8; BFDP 5.7%) and rs139882217 (HR 4.83; 95%CI 2.73 to 8.52; p=2.7x10-8; BFDP 69%) with hematuria. Previously published risk SNPs showed consistent associations in the cohorts not included in prior discovery GWAS: rs1801516 in ATM associated with overall toxicity (ß=0.05; 95%CI 0.01 to 0.09; p=0.016), rs17599026 in KDM3B associated with 2yr prevalence of increased urinary frequency (OR 1.27; 95%CI 0.95 to 1.70; p=0.10), rs7720298 in DNAH5 associated with 2yr prevalence of decreased urine stream (OR 1.26; 95%CI 0.94 to 1.70; p=0.13). A locus in TANC1 showed replication in some, but not all, new cohorts and warrants further investigation.

Conclusion: This largest GWAS to date identified novel risk SNPs and replicated previously identified SNPs. Further expansion of cohorts will uncover additional SNPs and allow development of risk models. Such models can be tested in clinical trials aimed at stratification of cancer patients based on toxicity risk profile.

Author Disclosure: S.L. Kerns: None. L. Fachal: None. M. Sydes: Honoraria; Eli Lilly. D. Dearnaley: Honorary contract; Royal Marsden NHS Foundation Trust. Honoraria; ICR MSc Course, Takeda, Millenium/Takeda, AMGEN, Astellas. Consultant; Millenium/Takeda. Speaker's Bureau; Takeda. Advisory Board; Janssen, Sandoz, AMGEN, Astellas. Travel Expenses; ICR MSc Course, Takeda, Millenium/Takeda, AMGEN, Astellas. Royalty; Institute of Cancer Research. Patent/License Fees/Copyright; Institute of Cancer Research. Senior Investigator; NIHR. Member; NHS R&D HTA College of Experts. M.B. Parliament: None. N.H. Usmani: Advisory Board; Astellas. In-kind Donation; Best Medical. K. de Ruyck: None. B.S. Rosenstein: Stock; Stock Mutual Funds. A. Gomez CaamaNo: None. P. Peleteiro Higuero: None. A. Vega: None. C.M. West: Honoraria; Merck. Travel Expenses; Merck. Chair of Trustee; LH Gray Memorial Trust. E. Hall: Research Grant; AstraZeneca, Bayer HealthCare Pharmaceuticals Inc, Accuray Inc, Aventis Pharma Limited (Sanofi), Kyowa Hakko UK, Alliance Pharma.

Sarah Kerns, PhD, MPH

University of Rochester Medical Center

Presentation(s):

Send Email for Sarah Kerns


Assets

TU_42_3728 - Meta-analysis of genome-wide association studies (GWAS) of late toxicity in 3,874 men treated with radiation for prostate cancer



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Meta-analysis of genome-wide association studies (GWAS) of late toxicity in 3,874 men treated with radiation for prostate cancer